Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir-Reference-Cited by-同舟云学术

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir

Published:2010-09-24 Issue:15 Volume:24 Page:2347-2354
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Gutmann Christine,Cusini Alexia,Günthard Huldrych F,Fux Christoph,Hirschel Bernard,Decosterd Laurent-Arthur,Cavassini Matthias,Yerly Sabine,Vernazza Pietro L

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference19 articles.

1. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy;Finzi;Nat Med,1999

2. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients;Umeh;Curr HIV/AIDS Rep,2005

3. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.;Havlir;N Engl J Med,1998

4. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).;Arribas;J Acquir Immune Defic Syndr,2005

5. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.;Vernazza;AIDS,2007

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy;Antioxidants;2024-04-26

2. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

3. Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective;AIDS;2021-12-15

4. CNS Considerations in ART Simplification Strategies;Current HIV/AIDS Reports;2021-11-05

5. Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks—A proof-of-concept study;PLOS ONE;2020-09-23